Costa Rica begins the clinical study of equine serum with 26 volunteer patients

Share on facebook
Share on twitter
Share on whatsapp
Share on telegram
Share on email

The Costa Rican Social Security Fund (CCSS) began, this Monday, the application of equine antibodies to patients with covid-19, reported the executive president, Dr. Román Macaya Hayes.

This is the “Randomized, controlled, double-blind, multicenter clinical study to compare the efficacy and safety of the administration of two formulations of equine anti-SARS-CoV-2 immunoglobulins (“ S ”and“ M ”) in hospitalized patients with COVID- 19 (SECR-01) ”, approved by the CCSS Central Scientific Ethics Committee, and was also declared a special project of institutional interest by the Board of Directors on August 20.

The owner stressed that the procedure, in its research phase, will begin with 26 hospitalized patients who must sign an informed consent. It will be applied in four medical centers: San Juan de Dios, Mexico, Rafael Ángel Calderón Guardia and the Center for Specialized Attention for Covid-19 Patients (CEACO). This Monday it was applied to two men and two women, aged 43, 66, 67 and 77.

The estimated time of recruitment of the patients is variable and depends on the fulfillment of inclusion criteria and the absence of exclusion criteria, it is expected in one week to have most of the participants established in the protocol.

Macaya explained that in a few weeks the first results will be known since this is an acute disease.

As he said these antibodies can inhibit SARS-CoV-2 before it causes sequelae, “we are not going to avoid hospitalizations because this is not an outpatient treatment, patients who have just entered the hospital will be applied to try to stop the evolution of the consequences of the virus so that they do not reach the intensive care units ”.

The hierarch indicated that if this procedure is effective, mortality could be lowered and the percentage of patients admitted to intensive care could be reduced, which would allow more bed rotation.

He stressed that having one’s own treatment, developed by Costa Rican scientists, is promising and this stage of clinical trials is really not only historical, “fills us with optimism.”

“Starting to infuse a covid-19 patient with a treatment developed in Costa Rica in a few months shows the great capacity of the human capital that the country has, the great institution that is the University of Costa Rica and obviously the Caja Costa Rican Social Security, this is a joint effort, “said the chief.

Latests News